{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-017018","form_type":"8-K","ticker":"DTIL","cik":"0001357874","company_name":"PRECISION BIOSCIENCES INC","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.909946+00:00","generated_at":"2026-05-15T13:06:25.881741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Precision BioSciences Q4 net income $20.1M, PBGENE-HBV shows antiviral activity, cash runway through 2028","bullets":["Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).","Cash, equivalents, restricted cash $137.2M as of Dec 31, 2025; $75M Nov 2025 financing extends runway through 2028.","PBGENE-HBV Phase 1: 13 patients dosed across 5 cohorts; late-breaking data showed safety, dose-dependent antiviral activity and HBsAg declines.","PBGENE-DMD received IND clearance Feb 2026; Fast Track & Orphan Drug designations; initial data from multiple patients expected year-end 2026.","Milestone payments: $8M from Imugene (Oct 2025) and $7.5M from TG Therapeutics (Mar 2026)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-017018","json":"https://secwatch.observer/filing/0001628280-26-017018.json","markdown":"https://secwatch.observer/filing/0001628280-26-017018.md","text":"https://secwatch.observer/filing/0001628280-26-017018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026017018/0001628280-26-017018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357874/000162828026017018/dtil-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:06:25.881741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}